Questcor Pharmaceuticals (QCOR -6.3%) says the number of paid prescriptions for its primary...

|By:, SA News Editor

Questcor Pharmaceuticals (QCOR -6.3%) says the number of paid prescriptions for its primary product, Acthar, dipped M/M in February. The result contrasts with the general pattern of explosive growth for Acthar, as QCOR has quickly built up its salesforce to promote the drug used to treat multiple sclerosis and other diseases.